Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AN2 Therapeutics Inc (ANTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: ANTX (1-star) is a SELL. SELL since 2 days. Profits (-8.09%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $1.67
1 Year Target Price $1.67
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -49.4% | Avg. Invested days 36 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.59M USD | Price to earnings Ratio - | 1Y Target Price 1.67 |
Price to earnings Ratio - | 1Y Target Price 1.67 | ||
Volume (30-day avg) 3 | Beta -0.08 | 52 Weeks Range 0.87 - 3.07 | Updated Date 06/29/2025 |
52 Weeks Range 0.87 - 3.07 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.51 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.49% | Return on Equity (TTM) -49.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -62806101 | Price to Sales(TTM) - |
Enterprise Value -62806101 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.11 | Shares Outstanding 30175700 | Shares Floating 22041855 |
Shares Outstanding 30175700 | Shares Floating 22041855 | ||
Percent Insiders 22.9 | Percent Institutions 36.89 |
Analyst Ratings
Rating 2 | Target Price 1.67 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
AN2 Therapeutics Inc
Company Overview
History and Background
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Founded in 2018, they went public in March 2023. They are currently focused on developing treatments for NTM lung disease and other related treatments.
Core Business Areas
- Drug Development: Focuses on the research and development of novel therapeutics.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates.
- Commercialization (Future): Plans for the future commercialization of approved therapies.
Leadership and Structure
The leadership team consists of key executives with experience in drug development, clinical research, and business management. The organizational structure is typical of a biotech company, with departments focused on research, development, clinical operations, and administration.
Top Products and Market Share
Key Offerings
- Epetraborole: Epetraborole is AN2 Therapeutics' leading drug candidate. It is used as treatment of NTM lung disease. Competitors are other antibiotics used off-label for NTM, but AN2 is looking for FDA approval of its own drug.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with companies constantly seeking to develop new and improved treatments for various diseases. There's a high unmet need for treating rare infectious diseases, and a growing market for novel therapeutics
Positioning
AN2 Therapeutics is positioned as a company specializing in rare and serious infectious diseases, aiming to address unmet medical needs through innovative drug development.
Total Addressable Market (TAM)
The NTM lung disease market is expected to grow. AN2 is positioned to capture a significant portion of this market if Epetraborole is approved.
Upturn SWOT Analysis
Strengths
- Focused on unmet medical needs in rare infectious diseases
- Novel drug candidate (Epetraborole)
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single lead drug candidate
- Limited commercialization experience
- High cash burn rate
- Relatively small company size
Opportunities
- Potential FDA approval of Epetraborole
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Growing market for rare disease treatments
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- TARO
- PFE
- MRK
Competitive Landscape
AN2 Therapeutics is a small player compared to larger pharmaceutical companies. Their competitive advantage lies in their focus on rare diseases and novel drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth as a relatively new company.
Future Projections: Future growth is tied to the success of Epetraborole and other pipeline programs. Analyst estimates vary depending on trial results and regulatory approvals.
Recent Initiatives: Focus on advancing Epetraborole through clinical trials and preparing for potential commercialization.
Summary
AN2 Therapeutics is a pre-revenue biopharmaceutical company focused on rare infectious diseases, particularly NTM lung disease. Its future heavily relies on the successful development and regulatory approval of Epetraborole. While the company has potential in a growing market, it faces risks related to clinical trial outcomes and competition from larger pharmaceutical firms. The company's long-term success is contingent on its ability to navigate regulatory hurdles and secure partnerships for commercialization.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AN2 Therapeutics Investor Relations
- SEC Filings
- Market Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share estimates may vary. All data is current as of the latest available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AN2 Therapeutics Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2022-03-25 | Co-Founder, CEO, President & Chairman of the Board Mr. Eric E. Easom | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://www.an2therapeutics.com |
Full time employees 22 | Website https://www.an2therapeutics.com | ||
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.